{"disease":{"id":"advanced-systemic-mastocytosis","name":"advanced systemic mastocytosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04695431","title":"Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM","phase":"","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03580655","title":"(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05609942","title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}